Journal: The Journal of Clinical and Aesthetic Dermatology

Article Title: Use of the 40-gene Expression Profile (40-GEP) Test in Medicare-eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs

doi:

Figure Lengend Snippet: ART usage (A) and costs in Medicare-eligible cSCC population (B).

Article Snippet: TOTALS PATIENT Total number of unique cSCC patients identified in IQVIA database (June 2021 to May 2022) 731,482 Total number of cSCC patients that received ART 9,313 Total normalized number of cSCC patients that received ART based on general population (1.8 million cSCC diagnosed annually)15–17 29,298 Total normalized number of cSCC Medicare (≥65 years) patients that received radiation treatment (83.6%) 22,917 RADIATION TREATMENT MODALITIES AMONG THE MEDICARE POPULATION COST OF ART COURSE ($) RAW # OF PATIENT IN IQVIA Image-guided radiation therapy (IGRT) 19 $60,774 1,391 Intensity-modulated radiation therapy (IMRT) 20 $95,047 4,849 Intensity-modulated proton therapy (IMPT) 21 $145,422 368 Radiation therapy (XRT) 22 $32,296 13,848 Weighted average cost for radiation treatment $60,693 Total cost of radiation for Medicare patients ~$1.39 billion Total cost of 40-GEP test for Medicare patients ~ $194 million Open in a separate window ART usage (A) and costs in Medicare-eligible cSCC population (B).

Techniques: